Cargando…

Efficacy of a Standardized Turmeric Extract Comprised of 70% Bisdemothoxy-Curcumin (REVERC3) Against LPS-Induced Inflammation in RAW264.7 Cells and Carrageenan-Induced Paw Edema

OBJECTIVE: It is well known that regular turmeric extract with 95% curcuminoid is comprised of curcumin (70.07%), desmethoxycurcumin (20.28%), and bisdemethoxycurcumin (BDMC) (3.63%). In the current study for the first time, we have enriched about 3% of bisdemethoxycurcumin (BDMC) to 70% as well as...

Descripción completa

Detalles Bibliográficos
Autores principales: Gouthamchandra, Kuluvar, Sudeep, Heggar Venkataramana, Chandrappa, Siddappa, Raj, Amrith, Naveen, Puttaswamy, Shyamaprasad, Kodimule
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966389/
https://www.ncbi.nlm.nih.gov/pubmed/33737826
http://dx.doi.org/10.2147/JIR.S291293
_version_ 1783665691993309184
author Gouthamchandra, Kuluvar
Sudeep, Heggar Venkataramana
Chandrappa, Siddappa
Raj, Amrith
Naveen, Puttaswamy
Shyamaprasad, Kodimule
author_facet Gouthamchandra, Kuluvar
Sudeep, Heggar Venkataramana
Chandrappa, Siddappa
Raj, Amrith
Naveen, Puttaswamy
Shyamaprasad, Kodimule
author_sort Gouthamchandra, Kuluvar
collection PubMed
description OBJECTIVE: It is well known that regular turmeric extract with 95% curcuminoid is comprised of curcumin (70.07%), desmethoxycurcumin (20.28%), and bisdemethoxycurcumin (BDMC) (3.63%). In the current study for the first time, we have enriched about 3% of bisdemethoxycurcumin (BDMC) to 70% as well as named it as REVERC3 and compared anti-inflammatory activity with regular turmeric extract using in vitro and in vivo models of inflammation. METHODS: To reveal the potential anti-inflammatory mechanism of action, we investigated nitric oxide (NO) scavenging, xanthine oxidase, and lipoxygenase inhibitory activity, further determined the level of pro-inflammatory cytokines, such as interleukin 6 (IL-6), tumor necrosis factor (TNF-α) and major inflammatory mediators like cyclooxygenase (COX-2) and inducible nitric oxide synthase (iNOS), inhibition in lipopolysaccharide (LPS) induced inflammation in RAW macrophage cells. In the other hand, a carrageenan-stimulated inflammatory rat model was carried out. RESULTS: Our study findings exhibited a significant anti-inflammatory activity of REVERC3 together with nitric oxide (NO), xanthine oxidase, and lipoxygenase inhibition. Further, we attenuated the levels of cyclooxygenase (COX-2), inducible nitric oxide synthase (iNOS), interleukin (IL-6) and tumor necrosis factor (TNF-α) expressions in the LPS-elicited RAW macrophage cells. REVERC3 showed a potential anti-inflammatory activity by inhibiting carrageenan induced paw edema after 4 hr at the dose of 100mg/kg body weight. CONCLUSION: Thus, our findings collectively indicated that the REVERC3 could efficiently inhibit inflammation compared to regular turmeric extract. Since bisdemethoxycurcumin is a stable molecule it could be effectively used in the applications of health care and the nutraceutical industry, indeed which deserves further investigations.
format Online
Article
Text
id pubmed-7966389
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-79663892021-03-17 Efficacy of a Standardized Turmeric Extract Comprised of 70% Bisdemothoxy-Curcumin (REVERC3) Against LPS-Induced Inflammation in RAW264.7 Cells and Carrageenan-Induced Paw Edema Gouthamchandra, Kuluvar Sudeep, Heggar Venkataramana Chandrappa, Siddappa Raj, Amrith Naveen, Puttaswamy Shyamaprasad, Kodimule J Inflamm Res Original Research OBJECTIVE: It is well known that regular turmeric extract with 95% curcuminoid is comprised of curcumin (70.07%), desmethoxycurcumin (20.28%), and bisdemethoxycurcumin (BDMC) (3.63%). In the current study for the first time, we have enriched about 3% of bisdemethoxycurcumin (BDMC) to 70% as well as named it as REVERC3 and compared anti-inflammatory activity with regular turmeric extract using in vitro and in vivo models of inflammation. METHODS: To reveal the potential anti-inflammatory mechanism of action, we investigated nitric oxide (NO) scavenging, xanthine oxidase, and lipoxygenase inhibitory activity, further determined the level of pro-inflammatory cytokines, such as interleukin 6 (IL-6), tumor necrosis factor (TNF-α) and major inflammatory mediators like cyclooxygenase (COX-2) and inducible nitric oxide synthase (iNOS), inhibition in lipopolysaccharide (LPS) induced inflammation in RAW macrophage cells. In the other hand, a carrageenan-stimulated inflammatory rat model was carried out. RESULTS: Our study findings exhibited a significant anti-inflammatory activity of REVERC3 together with nitric oxide (NO), xanthine oxidase, and lipoxygenase inhibition. Further, we attenuated the levels of cyclooxygenase (COX-2), inducible nitric oxide synthase (iNOS), interleukin (IL-6) and tumor necrosis factor (TNF-α) expressions in the LPS-elicited RAW macrophage cells. REVERC3 showed a potential anti-inflammatory activity by inhibiting carrageenan induced paw edema after 4 hr at the dose of 100mg/kg body weight. CONCLUSION: Thus, our findings collectively indicated that the REVERC3 could efficiently inhibit inflammation compared to regular turmeric extract. Since bisdemethoxycurcumin is a stable molecule it could be effectively used in the applications of health care and the nutraceutical industry, indeed which deserves further investigations. Dove 2021-03-12 /pmc/articles/PMC7966389/ /pubmed/33737826 http://dx.doi.org/10.2147/JIR.S291293 Text en © 2021 Gouthamchandra et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Gouthamchandra, Kuluvar
Sudeep, Heggar Venkataramana
Chandrappa, Siddappa
Raj, Amrith
Naveen, Puttaswamy
Shyamaprasad, Kodimule
Efficacy of a Standardized Turmeric Extract Comprised of 70% Bisdemothoxy-Curcumin (REVERC3) Against LPS-Induced Inflammation in RAW264.7 Cells and Carrageenan-Induced Paw Edema
title Efficacy of a Standardized Turmeric Extract Comprised of 70% Bisdemothoxy-Curcumin (REVERC3) Against LPS-Induced Inflammation in RAW264.7 Cells and Carrageenan-Induced Paw Edema
title_full Efficacy of a Standardized Turmeric Extract Comprised of 70% Bisdemothoxy-Curcumin (REVERC3) Against LPS-Induced Inflammation in RAW264.7 Cells and Carrageenan-Induced Paw Edema
title_fullStr Efficacy of a Standardized Turmeric Extract Comprised of 70% Bisdemothoxy-Curcumin (REVERC3) Against LPS-Induced Inflammation in RAW264.7 Cells and Carrageenan-Induced Paw Edema
title_full_unstemmed Efficacy of a Standardized Turmeric Extract Comprised of 70% Bisdemothoxy-Curcumin (REVERC3) Against LPS-Induced Inflammation in RAW264.7 Cells and Carrageenan-Induced Paw Edema
title_short Efficacy of a Standardized Turmeric Extract Comprised of 70% Bisdemothoxy-Curcumin (REVERC3) Against LPS-Induced Inflammation in RAW264.7 Cells and Carrageenan-Induced Paw Edema
title_sort efficacy of a standardized turmeric extract comprised of 70% bisdemothoxy-curcumin (reverc3) against lps-induced inflammation in raw264.7 cells and carrageenan-induced paw edema
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966389/
https://www.ncbi.nlm.nih.gov/pubmed/33737826
http://dx.doi.org/10.2147/JIR.S291293
work_keys_str_mv AT gouthamchandrakuluvar efficacyofastandardizedturmericextractcomprisedof70bisdemothoxycurcuminreverc3againstlpsinducedinflammationinraw2647cellsandcarrageenaninducedpawedema
AT sudeepheggarvenkataramana efficacyofastandardizedturmericextractcomprisedof70bisdemothoxycurcuminreverc3againstlpsinducedinflammationinraw2647cellsandcarrageenaninducedpawedema
AT chandrappasiddappa efficacyofastandardizedturmericextractcomprisedof70bisdemothoxycurcuminreverc3againstlpsinducedinflammationinraw2647cellsandcarrageenaninducedpawedema
AT rajamrith efficacyofastandardizedturmericextractcomprisedof70bisdemothoxycurcuminreverc3againstlpsinducedinflammationinraw2647cellsandcarrageenaninducedpawedema
AT naveenputtaswamy efficacyofastandardizedturmericextractcomprisedof70bisdemothoxycurcuminreverc3againstlpsinducedinflammationinraw2647cellsandcarrageenaninducedpawedema
AT shyamaprasadkodimule efficacyofastandardizedturmericextractcomprisedof70bisdemothoxycurcuminreverc3againstlpsinducedinflammationinraw2647cellsandcarrageenaninducedpawedema